On the 14th of October 2021 the vaccine specialist VEROVACCiNES GmbH completed their Mid-Seven-Figure Series B financing round with investors from Germany and Switzerland. According to the company these funds will be used to further validate the innovative platform technology as well as the portfolio of animal vaccines.

More information can be found here.